Genetrack Biolabs, working in partnership with Canada’s Michael Smith Genome Sciences Centre as part of a landmark research–industry collaboration, has announced the development of a revolutionary cancer testing platform called GenTraceDx™. Instead of providing a single snapshot of someone’s cancer, this innovative technology delivers ongoing genomic updates that allow doctors track how the disease is changing over time and make more precise, informed treatment decisions
GenTraceDx has been selected for national funding through Genome Canada’s Genomics Applications Partnership Program (GAPP), with approximately $6 million in funding provided through Genome Canada, Genome British Columbia and Genetrack Biolabs.
A New Era in Cancer Care: From Static Reports to Living Diagnostics
Everyone’s cancer care journey is uniqueEven within the same cancer type, each patient’s tumour is driven by a unique combination of genetic changes. Yet today, most cancer tests analyze only a limited set of genes and provide a single static report.
As a result, many patients are told there are “no actionable findings”, not necessarily because options do not exist, but because current testing approaches are limited, and reports quickly become outdated as new treatments, discoveries and clinical trials emerge.
GenTraceDx is designed to change that.
Instead of a one-time report, GenTraceDx introduces the world’s first “living cancer diagnostic”, a system that continuously reanalyzes each patient’s tumour data as new therapies, trials, and scientific discoveries emerge, ensuring they never miss a new treatment opportunity.
More Comprehensive Testing. More Opportunities. More Hope.
GenTraceDx is being built using one of the most comprehensive approaches available:
- Matched tumour–normal whole-exome sequencing (WES)
- Whole-transcriptome RNA analysis
This allows physicians to understand not only what genetic changes exist, but how those changes are actively influencing the cancer.
From there, the platform continuously analyzes global medical knowledge, including:
- New therapies and drug approvals
- Clinical trials worldwide
- Biomarker discoveries
- Emerging scientific research
When a new treatment or opportunity becomes relevant to a patient, physicians and patients are automatically notified in real time.
“GenTraceDx transforms cancer testing from a static snapshot into a living system that evolves with each patient’s journey,” said Dr. June Wong, industry lead of the project and CEO of Genetrack Biolabs. “GenTraceDx is designed to ensure that patients and physicians remain connected to the most current and relevant treatment opportunities throughout the entire cancer journey.”
Built in Canada. Designed to Change Global Cancer Care
The GenTraceDx project represents a powerful Canadian collaboration between:
- Genetrack Biolabs: a 26-year leader in regulated diagnostics, medical device manufacturing and large-scale LDT testing infrastructure across North America
- Canada’s Michael Smith Genome Sciences Centre (GSC): a globally recognized leader in cancer genomics and clinical sequencing
Together, the partnership combines world-class scientific expertise with proven commercialization capability, positioning Canada at the forefront of next-generation precision oncology.
“This platform brings cutting-edge genomics and AI-driven interpretation into real-world clinical care,” said Dr. Steven Jones, scientific director at GSC. “It represents a new standard for how genomic information can be used to guide treatment decisions over time.”
National Pilot to Launch Across Canada
As part of the GAPP-funded initiative, GenTraceDx will conduct a 500-patient national pilot study, with patient enrolment expected to begin in fall 2026.
This pilot will:
- Be deployed across oncology centers throughout Canada
- Evaluate the platform in real-world clinical settings
- Support integration of GenTraceDx into oncology workflows nationwide
The program is designed to generate the clinical and operational foundation required to support broader adoption across the healthcare system.
A Platform with Global Potential
The global precision oncology market is projected to exceed USD $300 billion by 2030, yet remains dominated by limited, static testing approaches.
GenTraceDx is being developed to address these limitations by offering:
- More comprehensive molecular profiling
- Continuous clinical updates
- Canadian data sovereignty
- A scalable, clinic-ready platform
Beyond diagnostics, the platform has also demonstrated the potential to identify novel therapeutic opportunities, highlighting its future role in advancing personalized medicine.
A Call to Patients, Physicians, and Healthcare Partners
GenTraceDx represents a new level of precision, personalization and possibility in cancer care.
Patients, oncologists, and healthcare institutions across Canada are invited to learn more about the upcoming national pilot.
For inquiries and pilot participation:
email study@gentrace.com
About GenTraceDx
GenTraceDx is a next-generation precision oncology platform that combines comprehensive genomic profiling with a continuously updating AI-driven interpretation system. It is designed to transform cancer testing into a living clinical resource that evolves with each patient’s journey.
“Genetrack Biolabs, working in partnership with Canada’s Michael Smith Genome Sciences Centre as part of a landmark research–industry collaboration, has developed a revolutionary cancer testing platform called GenTraceDx™. Instead of providing a single snapshot of someone’s cancer, this innovative technology delivers ongoing genomic updates that allow doctors track how the disease is changing over time and make more precise, informed treatment decisions.”
“announced the development of…” was used since the platform is still actively being developed. Using “has developed” could imply that development is complete, which would not accurately reflect the current stage of the project.
The intent behind the phrase “Cancer is deeply personal” is to convey that even within the same cancer type, each patient’s tumour is driven by a unique set of genetic alterations. As a result, effective treatment decisions must be tailored to the specific molecular profile of each individual patient.
About Genetrack Biolabs
Genetrack Biolabs is a Canadian leader in regulated DNA testing and diagnostics, with over 26 years of experience in laboratory development, medical device manufacturing, and large-scale deployment of LDT clinical testing solutions across North America.
About Canada’s Michael Smith Genome Sciences Centre (GSC)
The GSC is a globally recognized leader in genomics research and clinical sequencing, pioneering advances in cancer genomics and precision medicine.
Contact
GenTraceDx
media@gentrace.com
www.gentrace.com